Moderna, Inc.
MRNA
Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, flu, respiratory syncytial virus, Endemic HCoV, and hMPV+PIV3ā¦ read more
Healthcare
Biotechnology
7 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$174.38
Price+176.97%
$111.42
1Y
Price
Market Cap
$69.192b
Large
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in USD.-562.1%
EBITDA Margin-539.3%
Net Profit Margin-388.3%
Free Cash Flow Margin-562.1%
EBITDA Margin-539.3%
Net Profit Margin-388.3%
Free Cash Flow MarginRevenue
$2.228b
+14.6%
1y CAGR-26.0%
3y CAGR-35.4%
5y CAGREarnings
-$3.151b
-11.7%
1y CAGR+11.2%
3y CAGR-30.7%
5y CAGREPS
-$7.98
-9.9%
1y CAGR+12.2%
3y CAGR-31.2%
5y CAGRBook Value
$6.761b
$10.961b
Assets$4.200b
Liabilities$1.235b
DebtDebt to Assets
11.3%
-0.4x
Debt to EBITDAFree Cash Flow
-$1.223b
+40.8%
1y CAGR+27.9%
3y CAGR-24.9%
5y CAGRNo items found.
Press Releases
Statements and updates from the company